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ABSTRACT 
Development of chemotherapeutic agent and boron 
carrying pharmaceutical based on HER2 specific targeted is 
important due to its role in enhancing cancer progression. The 
purpose of this study is to synthesize curcumin analogue, namely 
Pentagamaboron-0 (PGB-0) or 2,5-bis(4-boronic acid)benzylidine 
cyclopentanone, and to explore the cytotoxic activity on HER2 
overexpressed-cancer cells. MCF-7/HER2 was used as a model of 
HER2 overexpressed-cancer cells and NIH3T3 as normal cells. 
PGB-0 bound to ATP binding site of HER2 and EGFR based on 
molecular docking study. PGB-0 was synthesized resulting in 
33% yield and was confirmed by IR, 1HNMR, 13CNMR and                 
Mass spectroscopy. Based on MTT assay PGB-0 decreased          
cells viability on MCF-7/HER2 cells with IC50 value of 270µM            
but performed no effect on NIH3T3 cells. Cell cycle analysis 
revealed that PGB-0 increased sub-G1 accumulation. PGB-0 
decreased HER2 expression in a dose-dependent manner.                 
We conclude that the new compound PGB-0 inhibits cell            
growth through cell death induction and decreased HER2 
expression. Thus, PGB-0 is potential to be developed as a 
chemotherapeutic agent and boron carrying pharmaceutical 
targeted on the HER2 receptor. 
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INTRODUCTIONS 
HER2 is a transmembrane protein that is 
overexpressed in most human solid tumors 
such as breast, ovarian, endometrial, colon, and 
non-small cell lung cancer, prostate, and 
cervical cancer (English et al., 2013). Moreover, 
more than 20% cases of breast cancer are 
related with overexpression of HER2 protein 
and correlated with a worse survival of patients 
(Gibbs, 2000). The HER2 receptor is              
normally expressed in healthy cells and is 
responsible for the regulator in cell growth and 
differentiation (Yakes et al., 2002). Thus, HER2 
signaling becomes an interesting field to 
develop a molecular targeted therapy for 
cancer. 
Several chemotherapeutic agents targeted 
on HER2 receptor are developed. Trastuzumab 
is found to be the first antibody targeting 
HER2. However, 70% of patients who 
prolonged use of trastuzumab show a 
resistance phenomenon leading to a 
progression of metastatic cancer due to the 
increasing of EGFR expression (Meiyanto et al., 
2011; Vu and Claret, 2012). To overcome this 
resistance phenomenon, gefitinib and WZ4002, 
a known EGFR inhibitor are developed. 
However, the use of gefitinib and WZ4002 lead 
to a new EGFR mutation causing 
ineffectiveness therapy. Further, lapatinib is 
introduced to overcome all of the resistance 
phenomena. Lapatinib effectively works both 
on tyrosine kinase EGFR and HER2 as well as 
ER receptor (D’Amato et al., 2015). The finding 
of lapatinib becomes a new insight to develop a 
chemotherapeutic targeted as a dual inhibitor 
not only targeted to the HER2 receptor but 
also EGFR. Recently, several cases reported 
that some patients were resistant to         
lapatinib treatment (D’Amato et al., 2015). 
Therefore, development of an ideal 
chemotherapeutic agent targeted on both 
EGFR and HER2 receptor needs to be 
explored thoroughly. 
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Figure 1. Chemical Structure of 2,5-bis(4-
boronic acid)benzylidine cyclopentanone or 
Pentagamaboronon-0 (PGB-0). 
 
Curcumin is a potential candidate of a 
chemotherapeutic agent to overcome the 
resistance phenomena on cancer due to its 
potency as tyrosine kinase inhibitor, including 
HER2 (Hong et al., 1999). However, curcumin 
is unstable at pH above 6.5 caused by its              
active methylene group (Sardjiman et al., 1997). 
Pentagamavunon-0 (PGV-0) and 
Pentagamavunon-1 (PGV-1) are developed by 
modifying the active methylene groups into 
cyclopentanone to overcome curcumin 
instability. The previous study showed that 
curcumin, PGV-0, and PGV-1 possess 
cytotoxic effect and inhibit NFκB activation in 
vitro in MCF-7 breast cancer cells, as well as 
interact with the HER2 receptor in silico 
(Meiyanto et al., 2014). The interaction between 
HER2 receptor with PGV-0 and PGV-1 is 
mediated through the H-bond between O atom 
on carbonyl group of PGV-0, and PGV-1             
with N atom of Leu846 from the HER2 
receptor. Hence, the carbonyl group on 
curcumin analogues is an essential part                
of the HER2 inhibitory activity. In order               
to develop curcumin analogues as boron 
carrying pharmaceuticals for boron neutron 
captured therapy (BNCT) application, 2,5-
bis(4-boronic acid)benzylidine cyclopentanone 
or Pentagamaboronon-0 (PGB-0) (Figure 1)               
is designed by modifying the hydroxyl group  
on benzene system into boronic acid and the 
using of cyclopentanone structure to             
maintain the potential binding of PGB-0              
on HER2 receptor. In this study, we synthesize 
a new curcumin analog, PGB-0, and             
explored the cytotoxic activity on HER2 
overexpressed-cancer cells as a candidate of 
chemotherapeutic agent and boron carrying 
pharmaceuticals targeted on the HER2 
receptor.  
 
MATERIAL AND METHODS 
Molecular docking, PLANTS 
Molecular docking was performed by 
Protein-Ligand Ant System (PLANTS) 1.1 
software. The structure of EGFR (PDB ID: 
1XKK) and HER2 (PDB ID: 3PP0) proteins 
were downloaded from PDB. YASARA 
(http://www.yasara.org/viewdl.htm) was used 
for protein preparation and MarvinSketch 
(http://www.chemaxon.com/marvin/downloa
d-user.html) for ligand preparation. 
Visualization 2D and 3D performed by MOE 
2010 software (Licensed by Faculty of 
Pharmacy, Universitas Gadjah Mada). 
 
Synthesis of 2,5-Bis(4-Boronic Acid) 
Benzylidine Cyclopentanone 
Eighty µL of cyclopentanone (Sigma) 
and 2mL of NaOH (Merck) 10% were mixed in 
5mL of ethanol (Merck). Three hundred mg of 
4-formylphenyl boronic acid (Sigma) was added 
then the mixture was stirred at 0°C for 30min. 
After settling for 1h, the mixture was 
neutralized by adding HCl 10% dropwise. The 
solid material was washed with ethanol:water 
1:1 and filtered. The melting point of the 
compound was determined by Buchi 
instrument. Thin layer chromatography 
experiment was performed by using Silica   
Gel 60 GF254 (Merck) and mobile phase 
methanol:chloroform 3:1 with detection by 
UV light. HPLC analysis was conducted by 
C18 column (chromosorb) and mobile phase 
acetonitrile:water (40:60) with UV detector at 
wavelength 254 nm. The structure elucidation 
was carried out by using 1H NMR and 13C 
NMR (JEOL DELTA 500 MHz), IR 
spectrophotometry (Perkin-Elmer), and MS 
(Shimadzu). 
 
Cell culture 
MCF-7/HER2 was kindly gifted from 
Prof. Yoshio Inouye (Departement of Surgery, 
Toho University School of Medicine, Japan) 
through Prof. Masashi Kawaichi (Laboratory of 
Gene Function in Animals, NAIST, Japan). The 
cells NIH3T3 was kindly given by Prof. Masashi 
Kawaichi (Laboratory of Gene Function in 
Animals, NAIST, Japan). Cells were grown in 
Dulbecco’s Modified Eagles Medium (DMEM) 
high glucose (Sigma) supplemented with 10% FBS  
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(Sigma), HEPES, sodium bicarbonate, 1.5% 
Penicillin-Streptomycin and 0.5% Fungizone 
(Gibco). Cells were incubated at 37°C with 5% 
CO2. 
 
Cytotoxicity assay  
Cells were seeded in 96-well plates with 
104 cells/well. After 24h incubation with PGB-
0 with various concentrations, the culture 
medium was removed and cells were washed in 
PBS (Sigma). Then, cells were incubated with 
0.5mg/mL MTT (Biovision) in 100µL culture 
medium each well for 4h.   MTT reaction was 
stopped by SDS reagent (10% Sodium dodecyl 
sulfate (Merck) in HCl 0.01N (Merck) and was 
incubated overnight. The absorbance was 
measured by ELISA reader (Bio-Rad) at a 
wavelength of 595nm (Mosmann, 1983). 
 
Cell Cycle Distribution Analysis 
An amount of 5x103 cells/well cells  
were distributed to 6-well plate in DMEM 
medium. After 24h incubation, cells were 
treated with PGB-0 ½ IC50 (135µM) and PGB-
0 IC50 (270µM). Following 24h treatment, cells 
were trypsinized and centrifuged with speed 
365g for 3min. Cell pellets were collected then 
were washed with a buffer solution as described 
by the manufacturer (BD Cycletest™ Plus             
DNA Kit; BD Biosciences, San Jose, USA). 
The treated cells suspension then was      
subjected to FACS Calibur (BD Bioscience) 
flowcytometer. 
 
Immunoblotting 
MCF-7/HER2 cells (1x104 cells) were 
incubated in tissue culture dish and was treated 
with PGB-0 (50µM and 150µM) for 24h. Total 
protein cell lysates were prepared by using 
radioimmunoprecipitation assay (RIPA) buffer 
(Santa Cruz #sc-364162) on ice. The cells 
suspension was sonicated and was centrifuged 
at 16000g for 20min at 4°C. The protein 
samples were denatured in 5x sample buffer 
and were subjected to 10% SDS-polyacrylamide 
gel electrophoresis. The separated proteins 
were transferred into PVDF membrane 
followed by blocking with 5% skim milk 
powder (w/v) in TBS (20mM Tris and 133 mM 
NaCl, 1M HCl) with 20% Tween 20 for 1h at 
room temperature. The membrane was probed 
using primary antibodies as follows: HER2 
antibody (Santa Cruz #sc-52349) and α-tubulin 
antibody (Santa Cruz #sc-32293) overnight at 
4°C followed by HRP-secondary antibodies 
mouse (Cell signaling #7076) for 1h at room 
temperature and was visualized by Amersham 
ECL Prime (#RPN2232). 
 
Analysis 
Cytotoxicity study was analyzed by determining 
IC50 value. Cell cycle distribution was acquired 
by using Modfit LT 4.1.7. Method validation 
of molecular docking was conducted by 
measuring Root Mean Square Distances 
(RMSD) heavy atom ligand with copy 
ligands. If RMSD value higher than 2.0 Å 
means that the molecular docking method is 
valid. The affinity of the compound was 
evaluated by identifying fPLP score. The lower 
fPLP score showed higher affinity of the binding 
and vice versa. 
 
RESULTS AND DISCUSSION 
Molecular Docking Study of PGB-0 on 
EGFR and HER2  
 
Table I. fPLP Score of PGB-0 on EGFR and 
HER2 
 
Ligand 
EGFR RMSD:  
1.91 
HER2 RMSD:  
0.95 
Lapatinib -150.04 -119.55 
Curcumin -88.83 -96.51 
PGB-0 -82,20 -82.37 
 
Our main purpose of this research is to 
develop a new compound having cytotoxic 
activites to specific cancer cells especially 
HER2 overexpressed cells. Firstly, we used 
molecular docking to construct our             
hypotesis regarding the spesific activities           
of our candidates to the target protein.             
We obtained that PGB-0 possessed potential 
candidate beside the other compounds           
(data not sown). Validation result showed 
molecular docking protocol was valid with 
RMSD value <2 Å (Table I). fPLP score of 
PGB-0 was higher than lapatinib and curcumin 
on (Table I). However, PGB-0 possessed 
shorter binding distance than lapatinib at Thr 
862 on the HER2 receptor (Table II). 
Compared to curcumin, PGB-0 also possessed  
more  binding  amino             acid  residues (Figure 2).  
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PGB-0 interacts on the same amino acid 
residue with curcumin (Glu 906) and possessed 
a shorter bonding distance on EGFR receptors. 
However, when compared with lapatinib,  
PGB-0 bond on different amino acids and a 
longer bonding distance. (Table 3). Based          
on the result, we predicted that PGB-0  
possibly bound to ATP-binding site of HER2 
and EGFR with different binding properties 
compared to lapatinib and curcumin. 
Therefore, PGB-0 is a potential candidate of 
chemotherapeutic agent targeted on HER2 and 
EGFR. 
 
Synthesis of PGB-0 
Based on the molecular docking results, 
PGB-0 possesed comparable affinity on EGFR 
and HER2 with lapatinib and curcumin, 
therefore in the next step we synthesize PGB-0. 
In order to obtain the PGB-0 compound in 
high purity, we performed several synthesis 
optimizations (data not shown). Disconnection 
analysis of PGB-0 showed that PGB-0 
predicted to be synthesized by reacting 4-
formylphenylboronic acid and cyclopentanone 
based on aldol condensation reaction             
(Scheme 1). PGB-0 compound was attained 
33% yield. HPLC analysis showed that the 
purity of product was observed on 4 min with a 
high percentage (95%) while the starting 
material 4-formylphenyl boronic acid was 
observed in low percentage at Rt of 2min (5%)  
(Figure 3). The hRf of the product based on the 
experiment was 75. The product profile was 
described as follows: mp > 200oC, 1H-NMR 
(CD3OD): δ 3.17 (s, J=3.27, 4H, C-CH2-CH2-
C), 4.7 (s, J=0.68, 1H, -OH), 7.5 (s, J=1.75, 2H, 
), 7.6 (s, J=3.14, 4H, -CH-CH-CH-CH-), 7.7 (s, 
J=1.23, 2H, -CH-C-), and 7.8 (s, J=1, 1H, -C-
CH-C).13C-NMR (CD3OD): δ 27.7 (s, -CH2), 
131 (s, -C-B-), 135 (s, -CH-), 135.1 (s, -CH-C-), 
135.4 (-C-CH-), and 139 (s, -C-C=O-); IR (KBr 
film) cm-1: 1620 (C=O), 3363 (OH), 1689 
(C=C alkene), 1550 (C=C aromatic), 624 (C-H 
alkene). MS of the product was found 347.14, 
calculated 347.97. 
Table II. Binding Interaction of Ligand on HER2 
 
Ligand Ligand Atom Residue Binding Type Distance 
Lapatinib 
N Leu 846 H-don 2.83 
N Ser 907 H-don 1.14 
N Thr 911 H-don 2.96 
O Ser 783 H-acc 1.62 
O Ser 783 H-acc 2.98 
N Thr 862 H-acc 2.80 
O Thr 862 H-acc 3.02 
O Thr 911 H-acc 2.89 
Curcumin O Leu 806 H-acc 2.03 
PGB-0 
O Lys 860 H-don 2.53 
O Glu 914 H-don 1.05 
O Ala 848 H-acc 2.19 
O Thr 862 H-acc 2.47 
 
Table III. Binding Interaction of Ligand on EGFR 
 
Ligand Ligand Atom Residue Binding Type Distance 
Lapatinib O Arg 841 H-acc 2.20 
Curcumin 
O Glu 906 H-don 2.61 
O Cys 775 H-acc 2.81 
PGB-0 O Glu 906 H-don 2.21 
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Lapatinib 
  
Curcumin 
 
  
PGB-0 
  
 EGFR HER2 
 
Figure 2. Visualization of ligand interaction on EGFR and HER2. The representative pose of 
lapatinib, Curcumin, and PGB-0. All ligand is depicted as balls and sticks. Green and purple cavity 
represent polar and hydrophobic interaction. Molecular Interaction was performed using MOE. 
 
 
 
 
Scheme 1. (A) Disconnection analysis of PGB-0 (i). PGB-0 was synthesized by reacting 
cyclopentanone (ii) and 4-formylphenyl boronic acid (iii) by aldol condensation reaction. (B) 
Reaction Mechanism of PGB-0. Cyclopentanone possessed as nucleophile while 4-formylphenyl 
boronic acid as an electrophile. The reaction started to form one side of PGB-0 followed by the 
second side.  
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Figure 3. HPLC profile of PGB-0. The sample 
was running on C18 with mobile phase 
acetonitrile:water (40:60) with UV detector at 
wavelength 254nm. 4-formylphenyl boronic 
acid (i) and PGB-0 (ii)  
 
Cytotoxic effect of PGB-0 on MCF-
7/HER2 and NIH3T3 Cells. 
The cytotoxic assay was carried out to 
evaluate the cytotoxicity of PGB-0 on HER2 
overexpressed-breast cancer cells and normal 
cells. The cytotoxic effect of PGB-0 was 
conducted by MTT assay. PGB-0 inhibited cells 
growth of MCF-7/HER2 with an IC50 value of 
270µM and performed no effect on NIH3T3 
normal cells (Figure 4). The cytotoxicity of 
PGB-0 was possibly through cell cycle arrest or 
apoptosis induction.  
 
 
 
Figure 4. Cytotoxic effect of PGB-0 on 
NIH3T3 and MCF-7/HER2 cells. Cells 
viability was determined by using MTT assay as 
stated in the method. The graph represented 
the correlation between concentration and cells 
viability  of   PGB-0. After  regression analysis  
(P<0.05), we obtained IC50 of PGB-0 on MCF-
7/HER2 was 270 µM. Data expressed as             
the mean ± standard error of the mean  (SEM) 
from three independent experiments. 
 
Effect of PGB-0 on Cell Cycle Modulation 
To evaluate the cytotoxicity of PGB-0 
whether caused by cell cycle arrest in            
MCF-7/HER2 cells, we performed flow 
cytometry analysis using PI staining. Cell             
cycle analysis revealed that PGB-0 increased 
cells accumulation in Sub-G1 phase (Figure 5). 
This phenomenon needed  to be confirmed               
by apoptosis assay to determine sub-G1            
cells accumulation due to apoptosis cells or 
necrosis. 
 
 
 
 
 
Figure 5. The Effect of PGB-0 on Cell Cycle 
Progression of MCF-7/HER2. Cells were 
seeded in 6-well, harvested after 24h of 
treatment, stained with propidium iodide and 
DNA content were analyzed by using flow 
cytometry as described in method (A) The 
profiles of cells in sub-G1, G1, S and G2-M 
phase of (i) control, (ii) PGB-0 135µM (iii) 
PGB-0 270µM. X-axis showed the DNA 
content and the Y axis showed the relative cell 
numbers. (B) Quantification of cell distribution 
in each phase. 
 
PGB-0 Decrease HER2 Expression 
We performed western blot of HER2 to 
confirm whether the cells growth inhibition by 
PGB-0 was related to HER2 expression.  Based  
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on results, PGB-0 50μM did not affect HER2 
expression. However, after treatment of PGB-0 
150μM, HER2 expression was decreasing 
(Figure 6).  
 
HER2  
α-tubulin  
Untreated           + 
PGB-0 50µM              + 
PGB-0 150µM                + 
 
Figure 6. Effect of PGB-0 on the HER2 
expression on MCF-7/HER2 cells using 
western blot. Cells were treated with a 
concentration of PGB-0 50μM and 150 for μM 
24h, then was analyzed using Western Blot as 
described in methods. 
 
The purposes of this study are to 
synthesize and explore the anticancer activity of 
a new curcumin analogue, PGB-0 on HER2 
overexpressed-cancer cells. Our screening using 
molecular docking PLANTS revealed that 
PGB-0 possibly bound to ATP binding site of 
EGFR and HER2. Lapatinib and Curcumin 
were used as a native ligand. Although fPLP 
score of PGB-0 is higher than lapatinib and 
curcumin, the binding distance of PGB-0 on 
both HER2 and EGFR is shorter than lapatinib 
and curcumin. Hence, we found that PGB-0 is 
comparable with lapatinib and curcumin to 
bind on ATP binding site of HER2 and EGFR 
based on molecular docking study. We succeed 
to synthesize PGB-0 with a simple method and 
reproducible. Synthesis strategy of PGB-0 is 
similar with common curcumin analogues 
synthesis which is based on aldol reaction. 
However, several factors such as mixing speed, 
temperature, pH, and the presence of boric acid 
on PGB-0 structure need to be controlled to 
minimize the by-product. Boric acid easily 
reacts with the other boric acid to produce 
boroxine (Nishiyabu et al., 2011). Our result 
demonstrated that PGB-0 inhibited cells 
growth of HER2 overexpressed-cancer cells 
and performed no effect on normal cells. 
According to the IC50 values, the cytotoxicity    
of   PGB-0    is    less   potent    than   lapatinib             
 
(IC50 = 8µM) and curcumin (IC50= 25µM) (the 
data was not shown). However, commonly, the 
requirement of chemopreventive and co-
chemotherapeutic agents only need a 
compound possessing specific target in cancer 
cells (Meiyanto et al., 2014). On the other hand, 
boron carrying pharmaceutical also requires 
non-cytotoxic compound to minimize the non-
selective toxicity to the patient (Barth, 2005). 
Thus, the less cytotoxicity of PGB-0 tends to 
be an advantage compared to lapatinib and 
curcumin. Curcumin and its analogues are well 
known inducing G2/M arrest (Meiyanto et al., 
2014) though, PGB-0 induced  sub-G1 cells 
accumulation. Cells in sub-G1 phase were 
described as a hypodiploid cell with low DNA 
content due to the DNA fragmentation and 
possibly apoptotic cells. Therefore, sub-G1 
accumulation induction by PGB-0 need to be 
confirmed by apoptosis assay. 
HER2 is a transmembrane receptor that 
also disrupts both the intrinsic and extrinsic 
apoptotic pathways (Carpenter and Lo, 2013).  
In extrinsic pathway, HER2 suppresses the 
apoptosis cell in the response to TNF-α. HER-
2 activates PI3K-Akt signaling then Akt-
mediated that leads to activation of NFκB to 
transcript anti-apoptosis protein. In the western 
blot, the result revealed that PGB-0 decreased 
the expression of HER2. This result is not the 
first report that curcumin and its analogues or 
related groups possessed activity as HER2 and 
tyrosine kinase inhibitor. Meiyanto et al., (2014) 
reported that curcumin and PGV-1 inhibit 
HER2 proteins, resulting in inhibition of NF-
κB activation. Determination of another kinase 
protein related to HER2 pathway is needed to 
confirm the molecular mechanism of PGB-0 
on HER2 overexpressed-cancer cells. Overall, 
this study discovered PGB-0 inhibits cells 
growth on HER2 overexpressed-cancer cells 
through induction of cells death and decreasing 
HER2 expression. In the near future, the role 
of PGB-0 on the downstream protein of HER2 
and binding assay of PGB-0 on HER2 receptor 
is interesting to be explored further in order to 
develop PGB-0 as a chemotherapeutic agent 
and boron carrying pharmaceutical targeted on 
HER2 receptor. 
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CONCLUSION 
PGB-0 inhibits cells growth on HER2 
overexpressed-cancer cells through induction 
of cells death and decreasing HER2 expression. 
Further study must be established to evaluate 
the molecular mechanism of PGB-0 on HER2 
downstream mechanism. 
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